Search

Your search keyword '"Velders, Gerjo A."' showing total 25 results

Search Constraints

Start Over You searched for: Author "Velders, Gerjo A." Remove constraint Author: "Velders, Gerjo A."
25 results on '"Velders, Gerjo A."'

Search Results

1. The effect of administering preprocedural VITamin K on the international normalized ratio in patients anticoagulated with ACEnocoumarol (VITKACE-study): a prospective cohort study

2. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma

3. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

4. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

5. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

6. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

7. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

8. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

9. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

10. P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

12. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

14. P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

18. First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

20. Polycytemie bij een patiënte met een uterusmyoom

21. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

23. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

24. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

25. Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.

Catalog

Books, media, physical & digital resources